Get the Stockscreener App
109.75
0.02%
0.115
Nuvalent Inc stock is traded at $109.75, with a volume of 105.18K.
It is up +0.02% in the last 24 hours and up +17.66% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$109.86
Open:
$110
24h Volume:
105.18K
Relative Volume:
0.19
Market Cap:
$7.39B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-28.14
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
+2.57%
1M Performance:
+17.66%
6M Performance:
+49.52%
1Y Performance:
+14.11%
1-Day Range:
$107.79
$110.92
1-Week Range:
$105.64
$112.88
52-Week Range:
$55.53
$112.88
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
109.79 | 8.53B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
430.79 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
786.67 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
924.74 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.31 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-12-25 | Initiated | Canaccord Genuity | Buy |
| Oct-16-25 | Resumed | Stifel | Buy |
| Oct-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference - PR Newswire
Nuvalent (NUVL) Receives a New Rating from Truist Financial - The Globe and Mail
Nuvalent: Deerfield funds sell $70.8m in NUVL stock By Investing.com - Investing.com Nigeria
Nuvalent: Deerfield funds sell $70.8m in NUVL stock - Investing.com India
Nuvalent closes $500 million public offering of common stock By Investing.com - Investing.com South Africa
Nuvalent Closes Public Offering of Common Shares - MarketScreener
Nuvalent (NASDAQ: NUVL) closes $500M stock offering; 4,950,496 shares sold in public deal - Stock Titan
FDA accepts NDA for Nuvalent's zidesamtinib for non-small cell lung cancer - MSN
J.P. Morgan Sticks to Its Buy Rating for Nuvalent (NUVL) - The Globe and Mail
Four companies raise nearly $950M in follow-ons: Public Equity Report - biocentury.com
Nuvalent Announces $500M Stock Offering Pricing - The Globe and Mail
Biotech Stock Gets Booted in Latest Fund Update - AOL.com
Will Nuvalent Inc. stock keep outperforming rivalsJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
Why analysts upgrade Nuvalent Inc. stockJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com
Sidley Represents Nuvalent in Pricing of US$500 Million Public Offering - Legal Desire Media and Insights
Jefferies raises Nuvalent stock price target to $164 on promising cancer drug data - Investing.com Nigeria
[8-K] Nuvalent, Inc. Reports Material Event | NUVL SEC FilingForm 8-K - Stock Titan
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC - The Malaysian Reserve
Can Nuvalent Inc. stock surprise with earnings upsideWeekly Trade Report & Safe Capital Growth Plans - newser.com
Will Nuvalent Inc. stock reach Wall Street targetsPortfolio Return Report & Accurate Buy Signal Notifications - newser.com
FDA accepts Nuvalent’s zidesamtinib application for lung cancer treatment By Investing.com - Investing.com Nigeria
Nuvalent Insider Sold Shares Worth $2,065,030, According to a Recent SEC Filing - MarketScreener
Nuvalent Gets FDA Review of Zidesamtinib for ROS1-Positive Lung Cancer - MarketScreener
FDA accepts Nuvalent’s zidesamtinib application for lung cancer treatment - Investing.com
Nuvalent Executives Sell Over $4.6 Million in Stock - TradingView
Nuvalent Announces FDA Acceptance of New Drug Application for Zi - GuruFocus
CFO Balcom Sells 20,729 ($2.1M) Of Nuvalent Inc [NUVL] - TradingView
[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan
[424B5] Nuvalent, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Nuvalent announces FDA acceptance of new drug application for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC - MarketScreener
Can Nuvalent Inc. stock rebound after recent weaknessJuly 2025 Pullbacks & Weekly High Conviction Trade Ideas - newser.com
Nuvalent Announces Pricing of Public Offering of Common Stock - Eastern Progress
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Nuvalent (NUVL) - The Globe and Mail
Using economic indicators to assess Nuvalent Inc. potentialStock Surge & Free Technical Confirmation Trade Alerts - newser.com
What momentum indicators show for Nuvalent Inc. stockJuly 2025 Gainers & Safe Capital Growth Stock Tips - newser.com
Nuvalent Prices $500 Million Common Stock Offering - MarketScreener
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvalent Inc Stock (NUVL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Balcom Alexandra | Chief Financial Officer |
Nov 17 '25 |
Option Exercise |
49.85 |
20,000 |
996,962 |
81,734 |
| Balcom Alexandra | Chief Financial Officer |
Nov 18 '25 |
Option Exercise |
72.35 |
729 |
52,743 |
62,463 |
| Balcom Alexandra | Chief Financial Officer |
Nov 17 '25 |
Sale |
99.45 |
20,000 |
1,989,025 |
61,734 |
| Balcom Alexandra | Chief Financial Officer |
Nov 18 '25 |
Sale |
104.26 |
729 |
76,005 |
61,734 |
| Miller Deborah Ann | Chief Legal Officer |
Nov 17 '25 |
Option Exercise |
6.89 |
24,200 |
166,738 |
73,286 |
| Miller Deborah Ann | Chief Legal Officer |
Nov 17 '25 |
Sale |
105.50 |
24,200 |
2,552,999 |
49,086 |
0.22%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):